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The Oxford Classification of IgA Nephropathy (IgAN)
identified mesangial hypercellularity (M), endocapillary
proliferation (E), segmental glomerulosclerosis (S), and
tubular atrophy/interstitial fibrosis (T) as independent
predictors of outcome. Whether it applies to individuals
excluded from the original study and how therapy influences
the predictive value of pathology remain uncertain. The
VALIGA study examined 1147 patients from 13 European
countries that encompassed the whole spectrum of IgAN.
Over a median follow-up of 4.7 years, 86% received
renin–angiotensin system blockade and 42% glucocorticoid/
immunosuppressive drugs. M, S, and T lesions
independently predicted the loss of estimated glomerular
filtration rate (eGFR) and a lower renal survival. Their value
was also assessed in patients not represented in the Oxford
cohort. In individuals with eGFR less than 30ml/min per
1.73m2, the M and T lesions independently predicted a poor
survival. In those with proteinuria under 0.5 g/day, both M
and E lesions were associated with a rise in proteinuria to
1 or 2g/day or more. The addition of M, S, and T lesions to
clinical variables significantly enhanced the ability to
predict progression only in those who did not receive
immunosuppression (net reclassification index 11.5%).
The VALIGA study provides a validation of the Oxford
classification in a large European cohort of IgAN patients
across the whole spectrum of the disease. The independent
predictive value of pathology MEST score is reduced by
glucocorticoid/immunosuppressive therapy.
Kidney International (2014) 86, 828–836; doi:10.1038/ki.2014.63;
published online 2 April 2014
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IgA nephropathy (IgAN) is the most common glomerulone-
phritis in the world, being particularly frequent in Asia,
Australia, and Europe.1 Although large multicenter cohorts
of patients have been investigated in China,2 data from
Europe have been mostly limited to single-center studies.3–5
Therefore, this collaborative study aimed to create a large
European database of patients with IgAN to include clinical,
laboratory, and histological data followed over a prolonged
time frame.
The study was initially aimed to validate the Oxford
Classification of IgAN in a European cohort (VALIGA).
The Oxford Classification identified four pathological
features (mesangial hypercellularity M, endocapillary hyper-
cellularity E, segmental glomerulosclerosis S, and tubular
atrophy/interstitial fibrosis T, resulting in a MEST score) that
predicted renal outcome independently of clinical indicators
at the time of renal biopsy and during follow-up.6,7 These
findings were valid both in adults and children.8 The limited
number of patients (265 cases) and their heterogeneous
origin (from 11 countries in four continents) indicated a
need for validation in other cohorts. Several validation
studies have addressed this (reviewed in Roberts9); however,
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most of the studies have serious limitations of either small
cohort size or clinical features, which were likely to confound
the results.10–19 The inclusion criteria of the Oxford study,
X0.5 g/day initial proteinuria, X30ml/min per 1.73m2 esti-
mated glomerular filtration rate (eGFR) at renal biopsy, and
X1 year available follow-up were chosen to ensure that
a sufficient number of hard outcome events occurred within
a limited follow-up. This enabled the independent value
of pathology to be tested, avoiding overrepresentation of
individuals with advanced scarring and excluding rare forms
of IgAN with rapidly progressive course that might add
excess heterogeneity. By design, the Oxford study did not
include the whole spectrum of cases encountered in clinical
practice. It could not address, for instance, the great
proportion of the IgAN population presenting with normal
renal function and minimal proteinuria, a common scenario
where the need for renal biopsy is still debated. Similarly, the
opposite end of the spectrum was not included—that is,
patients with low GFR who may be expected to show
irreversible scarring at renal biopsy, likely beyond response to
immunosuppressive treatment, and at a point where evalua-
tion of risks against benefits may cast doubts on renal biopsy
need. Last, the diverse ethnic origin of the Oxford cohort
made the impact of ethnicity difficult to assess. We therefore
took advantage of the large European collaboration provided
by the Immunonephrology Working Group of the ERA-
EDTA to investigate whether the Oxford classification is valid
and applies across the spectrum of IgAN disease presentation
and diverse management.
The VALIGA study includes 1147 patients from 13
European Countries with unrestricted criteria at entry, except
biopsy-proven primary IgAN and adequate histology materi-
al available for review. This produced the largest single cohort
reported in the worldwide literature of patients with IgAN. It
was designed to address whether the Oxford pathology
indicators continue to have independent predictive value,
across the full clinical spectrum of IgAN disease and despite
different therapeutic approaches.
RESULTS
Clinical features at presentation and during follow-up
VALIGA reports data on 1147 patients with primary IgAN
(Table 1) from 55 centers in 13 Countries (Supplementary
Figure 1S and 2S online). All patients were resident in Europe,
and 97.5% were Caucasian. Patients’ mean age was 36±16
years, 174 (15%) were children, and 73% were male. At renal
biopsy, the mean eGFR was 75±34ml/min per 1.73m2.
Patients belonged mostly to stages 1, 2, and 3 chronic kidney
disease (CKD; 33, 30 and 28% respectively), whereas 9% were
in stage 4 or stage 5. Median proteinuria at renal biopsy was
1.3 (interquartile range, IQ 0.6–2.6) g/day; 20% of patients had
mild proteinuria o0.5 g/day, 20% had proteinuria X0.5 and
o1 g/day, 39% had proteinuria X1 and o3 g/day, and 21%
had proteinuria X3 g/day. The mean arterial pressure (MAP)
was 98±13mmHg, and 65% of the patients were hyperten-
sive and/or receiving antihypertensive medications.
Before renal biopsy, 39% of VALIGA patients had received
renin–angiotensin system blockade (RASB) and 10% gluco-
corticoids and/or other immunosuppressive drugs.
Patients were followed up for a median of 4.7 (IQ, 2.4–7.9)
years (Table 2). Time-average (TA) MAP was 96±9mm
Hg. The median number of antihypertensive medications
received during follow-up was 1.0 (IQ 0.7–2.0); 86% of
patients received RASB. TA proteinuria was 0.8 (IQ 0.4–1.6)
g/day. During follow-up, 43% of patients received oral
glucocorticoids, 16% received intravenous ‘pulse’ methyl-
prednisolone, and 13% received fish oil; 4% of patients
underwent tonsillectomy.
The rate of decline in renal function was 1.8±7.5ml/min
per 1.73m2/year. End-stage renal disease (ESRD) developed
in 135 patients (12%) (Table 2). The renal function survival
from the combined end point of 50% reduction in eGFR or
ESRD was 74% at 10 years and was significantly better in
children than in adults (83% compared with 73%, Po0.001).
A significant association was observed between data at
renal biopsy (eGFR, MAP, proteinuria), during follow-up
(TA-MAP and TA-proteinuria), and the outcomes (data not
shown). Notably, in the VALIGA cohort, TA proteinuria
o0.5 g/day was a significant marker of better outcome than
follow-up proteinuria between 0.5 and 1.0 g/day (Figure 1).
Central pathology review and clinicopathological
correlations
Twenty-eight percent of renal biopsies showed diffuse mesan-
gial hypercellularity (M1), 11% showed endocapillary hyper-
cellularity (E1), 70% showed segmental glomerulosclerosis
Table 1 | Baseline characteristics of the study cohort of 1147
patients with IgA nephropathy (IgAN)
Total number 1147
Age (years) 36±16
Pediatric subjects (% o18 years old) 15
Male (%) 73
Ethnicity (% Caucasian/African/Asian/other) 97.5/0.5/0.5/1.5
eGFR (ml/min per 1.73m2) 73±30
CKD stage 1 or 2*, 3, 4, 5 (%) 60, 28, 7, 2
MAP (mmHg) 98±13
SBP (mmHg) 131±23
DBP (mmHg) 81±12
Hypertensive subjects (%) 65
Proteinuria (g/day) 1.3 (0.6–2.6)
Proteinuria g/day (%)o0.5, X0.5 o1, X1 o3, X3 20, 20, 39, 21
Before biopsy immunosuppressive treatments 10
Before biopsy nonimmunosuppressive treatments
Prior tonsillectomy (%) 4
Prior RASB (%) 39
Abbreviations: CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; MAP, mean arterial blood pressure; SBP, systolic
blood pressure.
Results are expressed as mean±s.d., median (interquartile range), or percent.
Hypertensive patients and proteinuria units: see Materials and Methods and
definitions. RASB: renin–angiotensin system blockade by angiotensin-converting
enzyme inhibitors and/or angiotensin receptors blockers.
CKD stages 1 and 2 were grouped in one only category owing to inaccuracy of
MDRD measure of eGFR in stages 1 and 2.
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(S1), and 21% showed tubular atrophy/interstitial fibrosis
(T1 or T2). As T2 lesions were infrequent (3.6%),
T2 and T1 lesions were combined to increase the statistical
power. Arterial intimal thickening was detected in 28% of
biopsies. Only 11% showed cellular/fibrocellular crescents
and 7% showed necrosis, without a significant association
between these two features.
The frequency of MEST scores varied according to
particular clinical settings at renal biopsy—for example, in
patients with advanced CKD, and according to the level of
baseline proteinuria (Figure 2).
M, S, and T scores were strongly associated with protein-
uria, MAP, and eGFR at the time of biopsy (Supplementary
Table 1S online). E score was associated with proteinuria only
(Po0.002).
Correlations between pathology lesions and outcome
Within the VALIGA cohort, the value of the MEST score to
predict the rate of renal function decline, as well as survival
without ESRD, or 50% reduction in initial GFR was verified
(Table 3). The exception was the E lesion, which did not
predict any of the outcomes when addressing the entire
cohort. In particular, the E lesion was not predictive in the
subgroup that did not receive immunosuppression, as it was
in the original study. Table 3 shows the univariate and
multivariate results for the M, S, and T lesions using either
linear regression (rate of renal function decline) or Cox
regression (survival from a combined event). All univariate
and multivariate comparisons were significant, except for the
multivariate value of S using linear regression (although
significant using the survival model) and the multivariate
value of M using survival (although significant using the
linear model). The effect sizes of pathology findings were
reduced after adjustment for clinical variables (for example,
the hazard ratios (HRs) for the S and T lesions fell from 4.1
and 5.6 to 1.8 and 2.6, respectively).
Subgroup of patients with minimal proteinuria at renal
biopsy
The VALIGA cohort included 219 patients with IgAN and
initial proteinuria o0.5 g/day, a subgroup not included in
the original Oxford study (Supplementary Table 2S online).
At the time of renal biopsy, the mean age of these patients
was 32±17 years and 27% were children. Initial eGFR was
90±26ml/min per 1.73m2. All MEST lesions were signi-
ficantly less frequent in this subgroup compared with the
remaining cohort: M1 (15%), E1 (5%), S1 (50%), and T1/2
(6%; Figure 2). Initial and follow-up MAP values were lower
than the whole group. Immunosuppression and RASB were
given to 21 and 71% of these patients, respectively. Their rate
Table 2 | Follow-up data and clinical outcome of IgAN
patients enrolled
Follow-up data
Duration of follow-up: median (IQ; years) 4.7 (2.4–7.9)
TA-MAP (mmHg) 96±9
TA-SBP (mmHg) 129±14
TA-DBP (mmHg) 79±8
Median number of antihypertensive drugs 1.0 (0.8–2.0)
TA proteinuria (g/day) 0.8 (0.4–1.6)
TA proteinuria o0.5, X0.5 o1, X1 o1.5,
X1.5 o2, X2 (%)
29, 28, 25, 9, 19
Immunosuppression
Oral corticosteroids (%) 43
Intravenous ‘pulse’ methylprednisolone (%) 16
Other immunosuppression (%) 16
Any immunosuppression (%) 46
Nonimmunosuppressive treatments
RASB (%) 86
Fish oil (%) 13
Tonsillectomy (%) 5
Clinical outcome data
Rate of decline in renal function
(ml/min per 1.73m2/year)
 1.8±7.5
50% decrease in eGFR (%) 14
ESRD (o15ml/min per 1.73m2) (%) 12
50% decrease in eGFR or ESRD (%) 16
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration
rate; ESRD, end-stage renal disease; IgAN, IgA nephropathy; MAP, mean arterial
blood pressure; RASB, renin–angiotensin system blockade; SBP, systolic blood
pressure; TA, time average (see text for definition).
Results are expressed by mean±s.d., median (interquartile range), or percent as
appropriate. Means and medians are time-averaged (see Materials and Methods).
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Figure 1 | Predictive value in kidney survival* of time-average
proteinuria. *Combined end point of 50% decrease in estimated
glomerular filtration rate (eGFR) and/or end-stage renal disease
(ESRD). All comparisons were statistically significant (Po0.05).
Time-average proteinuria o0.5 g/day vs. 0.5–0.9 g/day: Po0.001.
Time-average proteinuria 0.5–0.9 g/day vs. 1.0–1.4 g/day: P¼ 0.001.
Time-average proteinuria 1.0–1.4 g/day vs. 1.5–1.9 g/day: P¼ 0.04.
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of progression was  1.2±6.6ml/min per 1.73m2/year,
and only 5% reached the combined outcome of 50%
reduction in renal function and/or ESRD. The only signi-
ficant MEST score predicting this outcome at univariate
analysis was endocapillary proliferation (E1); P¼ 0.04, HR
5.2 (1.1–25.9). No MEST score predicted renal outcome in
multivariate analysis, even when age was included in the
multivariate model.
In this cohort of patients with initial low proteinuria, we
calculated the risk of developing higher levels of proteinuria
during the follow-up as a surrogate end point. Both M and E
scores significantly influenced progression to levels of
proteinuria X1 and X2g/day (Figure 3). Mesangial hyper-
cellularity was significantly associated with the development
of proteinuria X1g/day, P¼ 0.012, HR 2.5 (1.2–5.1), and
proteinuria X2g/day, P¼ 0.01, HR 4.1 (1.4–12.0). Endoca-
pillary hypercellularity was significantly associated with the
development of proteinuria X1 g/day, P¼ 0.018, HR 2.8
(1.2–6.8), and proteinuria X2 g/day, P¼ 0.029, HR 4.2
(1.2–15.0). The HR of developing proteinuria X1 and
X2 g/day, with either M1 or E1, adjusted for MAP and
RASB were 2.3 (1.3–4.0), P¼ 0.004, and 3.5 (1.5–8.4),
P¼ 0.005, respectively.
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Figure 2 |MEST score distribution in the VALIGA cohort of patients with IgA nephropathy (IgAN). The whole cohort (A); patients with
advanced chronic kidney disease (estimated glomerular filtration rate o30ml/min per 1.73m2) (B); patients with proteinuria o0.5 g/day (C),
X0.5, and o1 g/day (D); patients with proteinuria X1 and o3 g/day (E); and patients with proteinuria 43 g/day (F). Renal biopsies were
scored according to Oxford classification: mesangial score 40.5 (M1), any endocapillary hypercellularity (E1), any segmental sclerosis (S1),
tubular atrophy, and interstitial fibrosis (T1 and T2), arterial intimal thickening (present), any crescent (present).
Table 3 | Correlations between pathological features and
outcomes
Rate of renal function
decline
Survival from renal failure
or 50% drop in eGFR
Univariate
(ml/min per
1.73m2/year)
Multivariate
 (s.d.)a
Univariate
hazard ratio
(95% CI)
Multivariate
hazard ratio
(95% CI)a
Mesangial proliferation
M0  1.29±7.49 1 1
M1  3.02±7.32  0.9 (0.5) 2.3 (1.7–3.0) 1.3 (0.9–1.7)
Po0.001 P¼ 0.04 Po0.001 P¼ 0.12
Segmental glomerulosclerosis
S0  1.15±5.46 1 1
S1  2.03±8.18  0.1 (0.5) 4.1 (2.6–6.5) 1.8 (1.1–2.9)
P¼ 0.03 P¼ 0.85 Po0.001 P¼ 0.02
Tubular atrophy/interstitial fibrosis
T0  1.36±7.29 1 1
T1–2  3.28±7.97  1.4 (0.6) 5.6 (4.2–7.5) 2.6 (1.8–3.6)
Po0.001 P¼ 0.01 Po0.001 o0.001
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate.
Mesangial score 40.5 (M1), any endocapillary hypercellularity (E1), any segmental
sclerosis (S1), tubular atrophy, and interstitial fibrosis (T1 and T2).
aMultivariate models are adjusted for initial eGFR, follow-up blood pressure, and
proteinuria.
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Subgroup of patients with reduced renal function
(o30ml/min per 1.73m2) at renal biopsy
The VALIGA cohort included 99 patients who were not
included in the original Oxford study because of a low initial
eGFR (Supplementary Table 3S online). Their age at biopsy
was 49±16 years, which was significantly higher than the
cohort mean (Po0.001). They presented with a greater initial
proteinuria (2.4 g/day) and MAP (108±16mmHg) and dis-
played M1, S1, and T1-2 lesions more frequently compared
with those with an initial eGFR X30ml/min per 1.73m2,
being detected in 41, 92, and 77% of the cases, respectively
(Figure 1). Only T1–2 correlated with proteinuria at renal
biopsy in this group (P¼ 0.04).
These individuals had a higher blood pressure during
follow-up despite receiving more antihypertensive drugs
compared with the rest of the cohort (Po0.001). RASB
was used in almost all patients (91%). Immunosuppressive
drugs were also used more frequently (60% vs. 44%,
P¼ 0.004). The clinical outcome of patients with eGFR
o30ml/min per 1.73m2 was significantly worse than in the
remaining patients, with a survival from a combined event of
only 50% at 5 years as opposed to 90% (Po0.001).
M1 and T1–2 were associated with a lower survival from a
combined event using univariate analysis. This significance was
maintained in a multivariate model including five variables (S
and E were excluded, as only eight patients presented with S0
and 11 with E1) and adjusted for initial eGFR, TA-MAP, and
TA-proteinuria: M1 was associated with an HR of a combined
event of 2.3 (1.2–4.2), P¼ 0.009. Results did not change when
age was included in the multivariate model.
Correlations between pathology and outcome in patients
with or without glucocorticorticoid/immunosuppressive
therapy
In the VALIGA cohort, 523 patients (46%) received gluco-
corticoid/immunosuppressive therapy and 622 (54%)
did not. Those who received such treatment had a lower
initial eGFR (70±32 vs. 76±29ml/min per 1.73m2,
P¼ 0.002) and higher initial proteinuria (1.9, IQ 1.0–3.5 vs.
0.9, IQ 0.4–1.9 g/day, Po0.001). Otherwise, they had similar
age, sex, ethnicity, and MAP (data not shown). However,
individuals who received immunosuppression also had a
greater prevalence of MEST lesions (M1, 32%; E1, 13%; S1,
78%, and T1/2, 25%) compared with untreated individuals
(M1, 24%; E1, 9%; S1, 63%; and T1–2 18%, Po0.05 for all
comparisons). The net reclassification index obtained by
adding pathology to clinical variables was 11.5% (Table 4,
Po0.001) in those who did not receive immunosuppression,
whereas it was  0.9% (P¼ 0.72) in those who did. To
further address the impact of glucocorticoid/immunosup-
pressive therapy on the predictive value of pathology, we
derived ROC curves using clinical, pathological, and
clinicopathological models in treated and untreated indivi-
duals separately (Supplementary Figure 3S online). The areas
under the curve in those without steroid/immunosuppressive
therapy were 0.65, 0.72, and 0.75 with logistic models using
pathology (M, S, T) or clinical (initial eGFR, TA-MAP, and
TA proteinuria) variables, or both, respectively. In those who
received immunosuppression, the areas under the curve were
0.57, 0.68, and 0.69, respectively. Hence, the added value of
pathology was evident in those who did not receive
glucocorticoid/immunosuppressive treatment, as the predic-
tive value of pathology was reduced in those treated by
immunosuppressive therapy.
DISCUSSION
The VALIGA collaborative study has provided the largest
reported cohort of patients with IgAN, unique in that
the clinical and pathology data of the enrolled patients were
categorized according to common criteria and centrally
reviewed. The 1147 patients with IgAN represent the full
spectrum of clinical presentations of this common but still
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Figure 3 | Impact of M and E scores on surrogate marker of kidney survival in low-grade proteinuria categories*. *Measured as change
in grade of proteinuria fromo0.5 toX1 g/day (left panel) and toX2 g/day (right panel) in patients with IgAN and mesangial hypercellularity
(M1) or endocapillary hypercellularity (E1), compared with those without these lesions (M0 and E0). The hazard ratios (HRs) of developing
proteinuria X1 and X2 g/day, with either M1 or E1, adjusted for mean arterial blood pressure (MAP) and the use of renin–angiotensin
system (RAS) blockers, were 2.3 (1.3–4.0), P¼ 0.004, and 3.5 (1.5–8.4), P¼ 0.005, respectively.
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challenging renal disease, encompassing, as in real clinical
practice, its variety in age, histologic renal damage, renal
function, proteinuria, blood pressure, and treatments. These
patients were followed up for an average of 4.7 years, which is
a reasonable duration, given their multicenter and interna-
tional origin, thus providing a sufficient follow-up period to
analyze renal functional decline and clinical outcomes.
The VALIGA cohort does not depict the ‘natural history’
of IgAN, but rather the ‘nowadays history’ of this disease
in Europe, as a large majority of patients were treated with
RASB, and almost half of them were treated with steroid/
immunosuppressive therapy. Moreover, almost 40% of
patients had received RASB and 10% received corticosteroids
before the renal biopsy. Early European randomized con-
trolled trials in IgAN showed benefits of RASB,20,21
corticosteroids,22–24 and immunosuppressants,25 leading to
the widespread use of these drugs in Europe, particularly in
proteinuric cases, commonly considered at risk for
progression.26 Even taking into account patient selection
bias, it is clear that the functional decline in the VALIGA
cohort is slower than that reported in previous European
studies,27,28 presumably at least in part because most of those
patients did not receive RASB or immunosuppressive
treatments. The VALIGA data set thus provided the
opportunity to explore the renal pathology risk factors of
IgAN across the full clinical spectrum of disease and under
current management practices.
In the VALIGA cohort, mesangial hypercellularity, seg-
mental sclerosis, and tubular atrophy/interstitial fibrosis were
confirmed to have a predictive value independent of clinical
data at renal biopsy and follow-up. Hence, the MST criteria
were fully validated. As expected, histological signs of chronic
and irreversible damage had the strongest association with
unfavorable outcome; however, features of active renal
disease also showed significant predictive value.
Endocapillary hypercellularity, observed in only 11%
of patients, did not independently predict clinical outcome
in the whole cohort. This was the same finding as in
the Oxford Classification study,6 as well as in a multicenter
North American study.12 In the latter two, there was an
interaction of endocapillary hypercellularity with steroid/
immunosuppressive therapy; however, this was not the case
in the VALIGA cohort. A number of factors may influence
this point. The frequency of endocapillary hypercellularity
was significantly associated with proteinuria at renal biopsy
and was found to be a risk factor for progression in patients
with low proteinuria (o0.5 g/day), suggesting that endo-
capillary hypercellularity may have a particular prognostic
value in early phases of IgAN. From the published validation
studies, endocapillary hypercellularity was rarely found to be
a risk factor for progression, with the exception of reports in
cohorts of patients who did not receive steroid or cytotoxic
therapy.29,30 We speculate that the widespread use of RASB
and even corticosteroids before renal biopsy might have
influenced the lack of correlation in VALIGA patients
between endocapillary hypercellularity and outcome.
Mesangial hypercellularity was confirmed to be a sig-
nificant factor for progression in the full spectrum of IgAN
enrolled in VALIGA, including patients with initial eGFR
o30ml/min per 1.73m2 and patients with mild proteinuria
at renal biopsy (o0.5 g/day). This appears to be a very
sensitive pathology marker, as it was also an independent
predictor of the surrogate end point measure of increased
risk of worsening proteinuria to 1 or 2 g/day, a well-accepted
risk factor for progression.26 The value of mesangial
hypercellularity as an independent risk for progression is
debated. It was not validated in relatively small groups of
patients with IgAN, in which more advanced CKD stages
were frequent.10,12 On the contrary, in a large Chinese cohort,
in which the criteria for renal biopsy also included mild
cases,2 mesangial hypercellularity was found frequently and
was an independent predictor of progression. Hence, in spite
of different ethnicities, in large cohorts of Chinese and
European patients mesangial hypercellularity was validated
as a significant factor affecting progression. In VALIGA
patients who received steroid/immunosuppressive therapy,
the predictive value of M1 was lost, suggesting that mesangial
hypercellularity may be a steroid-responsive lesion amenable
to such therapy, as reported in studies from Japan.31,32
Segmental sclerosis and tubular atrophy/interstitial fibro-
sis were also confirmed in the VALIGA cohort as risk factors
for poor prognosis, in agreement with almost all previous
validation studies. This is perhaps not surprising, particularly
when the end point considered is survival without ESRD,
as these lesions represent a more chronic and late stage of
Table 4 |Net reclassification index using pathology in
addition to clinical variables
Models with clinical and pathological variables
No
immunosuppression
Any
immunosuppression
Model with
clinical
variables only
Predicted
slow
progression
Predicted
rapid
progression
Predicted
slow
progression
Predicted
rapid
progression
Observed rapid progression
Predicted slow
progression
109 28 117 12
Predicted rapid
progression
13 177 10 98
Observed slow progression
Predicted slow
progression
204 6 206 14
Predicted rapid
progression
26 54 9 52
Abbreviations: GFR, glomerular filtration rate; M, mesangial hypercellularity;
S, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis.
Clinical variables include the time-average proteinuria, time-average mean arterial
pressure, and the initial GFR. Pathology variables include the M, S, and T lesions.
The net reclassification index obtained by adding pathology to clinical variables
was 11.5% in those who did not receive immunosuppression, whereas it was
 0.9% in those who did. Dark gray box: appropriate reclassification when adding
pathological variables to clinical variables. Light gray box: inappropriate reclassifi-
cation when adding pathological variables to clinical variables.
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IgAN renal damage. Notably, in patients with proteinuria
o0.5 g/day and well-preserved GFR, 71% of whom were
treated by RASB, mesangial and/or endocapillary hyper-
cellularity were more predictive of outcome than segmental
sclerosis and the rarely detected tubular atrophy/interstitial
fibrosis. This observation may suggest the advantage of an
early renal biopsy in subjects suspected to have IgAN,
although the risks of a renal biopsy and the cost–benefit ratio
have not been assessed in this specific context.
Crescents were found in a minority of cases, and their
presence, as defined in the Oxford cohort, was not found to
be of prognostic value. This conclusion is similar to several
other observations in large cohorts of Asian patients.2,33 It
may be that in presence of crescents more detailed case-by-
case analysis is needed, including the presence of associated
lesions and the clinical context. Moreover, crescents may
respond to immunosuppressive therapy, and hence their
prognostic value could be reduced by treatment.
The large number of cases enrolled in VALIGA allowed a
subanalysis of the MEST scores in selected cohorts of patients
presenting with different clinical features or receiving various
treatments. In the VALIGA cohort, the MST scores were
strongly associated with outcome only in patients who did
not receive steroid/immunosuppressive drugs, whereas this
effect was blunted in those who received this treatment.
There is a risk of over-interpreting the data from the VALIGA
cohort, as well as the Oxford and other recently published
studies, as all are retrospective series with uncontrolled doses,
time of initiation, and durations of therapies. Reports on
studies that include repeated renal biopsies have shown the
possibility of improvement of certain histological lesions,
including mesangial and endocapillary hypercellularity,
and crescents.33,34 A study from Korea, which evaluated
patients with IgAN who received steroid/immunosuppressive
treatment, found no predictive value of MEST scores,34
whereas the Oxford scoring system was fully validated in a
nontreated cohort from France.29 This was very similar to
our VALIGA data where the predictive value of the pathology
features in addition to the clinical data was evident only in
patients who did not receive steroid/immunosuppressive
treatment.
In conclusion, the VALIGA study has provided a
validation of the Oxford MEST score classification in a large
European cohort of patients with IgAN. The analysis of the
full spectrum of renal pathology features and clinical
conditions represented in this relevant cohort indicated that
the MEST score has to be considered in the light of both the
clinical features, including levels of proteinuria and GFR
values, and the treatments given before renal biopsy. It also
demonstrated that the postbiopsy therapeutic maneuvers are
likely to modulate some of the pathology risk factors.
MATERIALS AND METHODS
VALIGA is an European multicenter retrospective study of patients
with biopsy-proven primary IgAN with a follow-up 41 year or
who reached ESRD in less than 1 year. Renal biopsy review required
X8 glomeruli. All centers had ethical board approval.
Clinical spreadsheets recorded past history and baseline data
(within 3 months of the renal biopsy). Each renal biopsy was scored
by the local pathologist according to the Oxford classification.
Biopsy slides were rescored by the Pathology review center in
Oxford, UK, where the pathologists were blinded to clinical and
local pathology data. Centrally reviewed data were used for
statistical analysis.
Clinical data set and definitions
Children were subjects aged o18 years at biopsy. To provide
consistency between measurements in adults and children, protei-
nuria was expressed in g per 24 h per 1.73m2 in children and g per
24 h in adults. In children, blood pressure was adjusted for gender
and age, as in the original report.8 To replicate the Oxford study,
eGFR was estimated using the 4-variable MDRD formula in adults35
and the Schwartz formula in children (constant K¼ 0.55)36 with
a maximum eGFR set at 120ml/min per 1.73m2, as the accuracy of
eGFR for higher values is low37 and also as small variations in
creatinine can have a disproportionate impact on the rate of renal
function decline. ESRD was defined as eGFR o15ml/min per
1.73m2. MAP was diastolic blood pressure plus a third of systolic
blood pressure. For each child, the standard deviation score for
MAP was calculated and used to normalize MAP to adult values.8,38
Average MAP and proteinuria were determined for each 6-month
period of observation. TA MAP and TA proteinuria represent the
average of each period’s mean. Immunosuppressive treatment was
considered as intent to treat regardless of the type or duration of
therapy. RASB indicated treatment with either angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker or
both. Adults with SBP X140mmHg or DBP X90mmHg or those
on antihypertensive drugs were considered to be hypertensive, and
children with MAP exceeding the 95th percentile for height, sex and
age or on antihypertensive drugs were considered to be hypertensive.
Pathology review
Renal biopsies were scored according to the Oxford Classification:
mesangial hypercellularity, M0/M1 (o or equal to450% of glome-
ruli with 44 mesangial cells/area); endocapillary hypercellularity,
E0/E1 (present/absent); segmental glomerulosclerosis, S0/S1
(present/absent); tubular atrophy/interstitial fibrosis, T0/T1/T2
(o25%, 25–50%, 450%). In addition, arterial intimal thickening
and extracapillary proliferation with cellular or fibrocellular cres-
cents were categorized as present/absent according to the Oxford
report.6,7
Outcomes
Two clinical outcomes were considered to evaluate the predictive
value of renal pathology variables, the rate of renal function
decline (slope of eGFR) and survival from a 50% reduction in
renal function, or ESRD. In patients with an initial proteinuria
o0.5 g/day, increases in proteinuria to X1 or to X2 g/day were
considered surrogate outcomes, which is indicative of a poor
long-term outcome in comparison with the same cohorts whose
proteinuria did not increase during follow-up.23
Statistical methods
Normally distributed variables were expressed as mean±s.d. and
compared using Student’s t-test, one-way analysis of variance, or
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Pearson’s test. Nonparametric variables were expressed as median,
interquartile ranges (IQ) and compared either by Mann–Whitney,
Kruskal–Wallis, or Spearman’s test. Categorical variables were
expressed in percentages and compared using the Pearson w2 test.
The rate of renal function decline was determined by fitting
a straight line through available data for eGFR using the principle
of least squares. This was plotted and visually examined for each
patient. Obvious outliers were censored. Univariate analysis
followed by multiple linear regression was used to determine
independent predictors of slope. Survival analysis using Cox
regression was performed to test the association between each
pathology finding and a combined event (50% reduction in renal
function or ESRD) to increase the rate of events and to permit a
valid multivariate analysis. To allow comparison with the original
study, the same multivariate models were adopted, and these include
a model using pathology variables only (M, S, and T), one with
clinical variables only (initial eGFR, time average MAP and
proteinuria), and a final model including both pathological and
clinical features. We validated the same multivariate models from
the original Oxford classification study. These did not include the E
lesion, as it had showed a strong interaction with therapy and was
only predictive when considering individuals who did not receive
immunosuppression. The exposure to immunosuppressive treat-
ments (glucocorticoids or immunosuppressive drugs) was consid-
ered as presence versus absence.
To further assess how pathology adds predictive value, we
determined the net reclassification index.39 First, we dichotomized
the rate of renal function decline into a rapid or slow observed
progression based on the median slope. Second, rapid or slow
predicted progressions were determined for each individual using
two logistic models, one with clinical variables only and another
with both clinical and pathology variables. Finally, we assessed the
number of individuals who were reclassified, appropriately or not,
going from the regression model with clinical variables only to the
one with both clinical and pathological variables. The net reclassi-
fication index is calculated using probabilities (P) of reclassification
as follows: net reclassification index¼ P(correct reclassification |
rapid progression) – P(incorrect reclassification | rapid progre-
ssion)þ P(correct reclassification | slow progression) – P(incorrect
reclassification | slow progression). We also calculated the area
under the receiver-operating characteristic curves (c-statistic) for
these models using logistic regression.
All P-values were two-tailed, and values less than 0.05 were
considered statistically significant. Confidence intervals included
95% of predicted values. Analyses were carried out using the SPSS
software (version 11, SPSS, Chicago, IL).
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